Gemneo Bioscience, Inc. is developing novel genomic profiling technologies designed to enable personalized medicine and a better understanding of the heterogeneity of disease. The firm came out of a several year, multi-million dollar research effort at Arizona State Universitys Biodesign Institute structured around developing innovative molecular-based single-cell genomics technology that does not require cell sorting. This capability could greatly increase the speed and reduce the cost of analyzing the genomic heterogeneity of cancer and immune tissues, and microbiomes. Focused around advancing cost-effective precision medicine, and improved patient outcomes, the firm's work addresses DNA Origami Nanoprobes for single-cell multi-gene analysis and single-cell analysis of tumor heterogeneity. The effort is to employ Gemneos platform technology to profile cancer genomics and identify rare cells that influence disease progression that current technologies are not able to detect.
